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Transplantation techniques for patients with primary immunodeficiencies have improved
so that survival from the procedure in many cases is >80%. However, long term
complications may arise due to the use or not of conditioning agents. This may
result in variable immune reconstitution, the long term effects of chemotherapy,
particularly on fertility, and complications relating to the genetic disorder, unresolved
by transplantation. For patients with severe combined immunodeficiency (SCID), long
term T- and B-lymphocyte immune reconstitution is best achieved after pre-transplant
chemotherapy. For patients who receive an unconditioned infusion of donor stem cells,
the quality of immune reconstitution depends on the SCID genotype. Long term effects
include chemotherapy-induced impaired fertility, and sequelae specific to the genotype.
For patients with other primary immunodeficiencies, conditioning is required—sequelae
related to direct effects of chemotherapy may be observed. Additional long term effects
may be observed due to partial donor chimerism resulting in incomplete eradication of
disease, and other geno-specific effects.
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INTRODUCTION
Incremental improvements in the approach to transplantation have ensured that survival following
allogeneic hematopoietic stem cell transplantation (HSCT) for primary immunodeficiency (PID) is
now generally>80% (1–4). More accurate matching at HLA loci using molecular DNA techniques,
pre-emptive treatment of viremia, adoption of less toxic condition regimens and pharmacokinetic
monitoring (5–8), development of more effective T-lymphocyte depletion methods (9, 10), and
more effective treatment of transplant-related complications (11–13) now mean that the majority
of patients undergoing HSCT for PID can expect to survive the procedure. As a consequence of
this increase survival rate, more emphasis is being put on the quality of long term outcome. An
overview on both specific immuno-hematological as well as overall quality of health perspectives is
discussed below.
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SEVERE COMBINED IMMUNODEFICIENCY
Long Term Immune Function
The issue regarding long-term outcome is probably most
complex but also best studied in patients with severe
combined immunodeficiency (SCID). Severe combined
immunodeficiencies are a heterogeneous group of inherited
primary immunodeficiencies characterized by absent
thymopoiesis due to lack of T-lymphocyte progenitors
available to enter or to develop within the thymus, failure
of T-lymphocyte maturation and function, and thus severally
impaired cellular and humoral acquired immunity. Depending
on the genetic defect, recipient B-lymphocytes, and/or Natural
Killer cells may be present. The lack of T-lymphocytes, often
accompanied by significant infection, and end-organ damage
resulted in many patients receiving a stem cell infusion without
preparative chemotherapy to empty osteo-medullary and thymic
niches. Immune-reconstitution was reported to be variable,
and it is now clear that the outcome depends on the specific
SCID genotype and thereby the stage in which thymopoiesis
is arrested. Mature donor stem cell-derived T-lymphocytes,
transferred in the inoculum, populate the periphery, and expand
to confer medium-term but finite immune protection, with
a restricted T-lymphocyte receptor repertoire. Effective long-
term thymopoiesis with T-lymphocyte immune reconstitution
requires donor stem cell-derived T-lymphocyte progenitors
to enter the thymus and undergo proliferation during the
thymocyte double negative (DN) 1 and 2 stages, before
DN3, when thymocytes undergo rearrangement of the T-
lymphocyte receptor. The lack of recipient T-lymphocytes to
facilitate rejection and the concept of host osteo-medullary
and thymic environments which are either permissive or
non-permissive to engraftment following infusion (14, 15)
long provoked debate over approach to treatment. The debate
centers around whether infusion of donor stem cells, without
administering immunosuppressive and myeloablative pre-
transplant chemotherapy conditioning, is equally effective
and less toxic/more safe in realizing a long-term cure than
transplantation of donor stem cells following administration
of myeloablative chemotherapy conditioning. With careful
analysis of immune reconstitution in single (16–21), and
multi-center cohorts (1, 22, 23), there is emerging clarification
about which molecular diagnoses permit adequate long-term
thymopoiesis after graft infusion without conditioning, and
which genotypes of SCID likely require conditioning for best
long-term results.
Infusion without chemo-conditioning of replete marrow
from HLA-matched sibling or matched unrelated donors or T-
lymphocyte-depleted haplo-identical stem cells from parental
donors facilitates thymopoiesis and T-lymphocyte immune
reconstitution. This is particularly the case in patients with IL-
2 receptor gamma chain (IL-2Rγ)-, janus-associated kinase 3
(JAK3)-, or adenosine deaminase-(ADA) deficient SCID, and
leads to good survival (1, 15, 20, 21, 24, 25). Pre-thymic and
early intrathymic stromal niches are vacant with no competition
between donor progenitors and endogenous, immature, DN
thymocytes, which are absent in these SCID conditions. Thymic
niches are thus available for donor T-lymphocyte precursor
engraftment, leading to sustained donor-derived thymopoiesis in
the absence of myelopoiesis (26), which nevertheless may be of
finite durability (21). Donor B-lymphocyte engraftment usually
fails to occur because the osteo-medullary niche is occupied by
recipient B lineage pre-cursors and mature cells. In IL-2Rγ- and
JAK3-deficient SCID, recipient B-lymphocytes are functionally
impaired (27), and infused patients usually require long-term
immunoglobulin replacement. IL-7Rα-deficient patients usually
develop B-lymphocyte function, as recipient B-lymphocytes
have intact intrinsic function, and produce immunoglobulin
in the presence of functioning donor T-lymphocytes. Patients
with ADA-deficient SCID often develop cellular and humoral
immune reconstitution in the absence of conditioning, possibly
because the local toxic effects of ADA deficiency on the
marrow act as “auto-conditioning” combined with a selective
growth advantage and permit donor stem cell engraftment
in the absence of chemotherapy. Rare patients with a CID-
phenotype due to ADA deficiency require chemo-conditioning to
achieve engraftment.
Thymopoiesis and humoral immunity is infrequently
observed in unconditioned patients with NK+ SCID due to
defects in recombination activating genes 1 and 2- (RAG1/2)
and DCLRE1C (Artemis). In these patients, early T-lymphocyte
development is arrested at later stages of committed T-
lymphocyte differentiation creating a non-permissive thymic
environment occupied with high numbers of DN2/DN3 cells
competing with donor T-lymphocyte progenitors for thymic
niches. As a consequence SCID patients with these genetic defects
are refractory to thymic and B lineage reconstitution following
transplantation without conditioning because of competition for
thymic and osteo-medullary niches. Following infusion of donor
cells without conditioning, immune reconstitution is poor;
T-lymphocyte engraftment relies on post-thymic peripheral
T-lymphocyte expansion, with a failure of thymopoiesis, and a
restricted T-lymphocyte receptor repertoire (17, 18, 28).
Together, in the long-term, in unconditioned transplants,
superior thymopoiesis is observed in IL-2Rγ-, JAK3-, IL-7
receptor alpha- (IL-7Rα), or ADA- deficient SCID compared
with recombination activating genes 1 and 2- (RAG1/2) and
DCLRE1C (Artemis) -deficient SCID. However, in the absence
of pre-conditioning chemotherapy, donor B-lymphocyte, and
myeloid chimerism is generally absent in either group (14), with
the exception of ADA- deficient SCID (24).
As there is no survival difference between those patients
receiving chemotherapy conditioning and those receiving either
immunosuppression only, or no preparative regimen (1, 23), at
present, a chemotherapy conditioning preparation is preferred to
achieve donor stem cell engraftment and thus durable immune
reconstitution if the physical condition of the patient will allow
this. Durable T-lymphocyte reconstitution is associated with
better survival (29), good T-lymphocyte reconstitution at 1
to 2 years post-HSCT is associated with better T-lymphocyte
long-term immune reconstitution (18), and high T-lymphocyte
receptor excision (TREC) circle counts, markers of thymopoiesis,
at 6 months associate with robust long-term T-lymphocyte
reconstitution (1, 16, 17, 20, 21).
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The advantageous effect of conditioning on long term graft
and immune function also raises new challenges in the context
of the observation that infants treated in the 1st months of life,
before the onset of infection, have the most favorable outcome,
with a survival of >90%, and fewer long-term infectious, and
immune-related complications (22, 30). This is particularly
relevant given the ongoing implementation of SCID newborn
screening (NBS) programs in many countries worldwide (refer to
chapters on SCID/NBS). Whilst there is unease in the transplant
community about administering chemotherapy to young infants
to optimize engraftment and reconstitution, it is not clear what
the long term effects of such administration are, or at what age
these effects are likely to be less significant. One study using
treosulfan and fludarabine in infants <5 months of age showed
good survival and no significant early toxicity, although long
term effects will need to be evaluated (6). The routine adoption
of pharmacokinetic studies during chemotherapy delivery may
help answer some of the questions.
Although we may now have a better understanding of
how to avoid poor graft function, there are many surviving
patients living with the effects of poor immunity or sequelae
of post-transplant complications, such as graft-vs. -host disease.
There are few published data on this—one single center cohort
study of 90 patients describes chronic graft-vs. -host disease
in 10% of patients (31). Additionally, patients were described
with autoimmune and inflammatory conditions, and significant
infections. Within this cohort, about one third of patients did
require any form of long-term treatment (31). In another large
cohort study of 124 patients, over half of whom had IL-2Rγ-
and JAK3-deficient SCID, 86% of 111 survivors with follow
up were considered healthy by the physicians, although 53%
required long-term immunoglobulin replacement indicative for
incomplete immune correction. Other long-term complications
reported included autoimmunity, hypothyroidism, malignancy,
and developmental delay (30).
Long Term Sequelae in SCID Patients
In transplanted SCID patients several long-term sequelae are
directly related to the underlying genetic defect as part of their
syndromal disease, and occur independent of the immune-
hematological defect, and reconstitution characteristics after
stem cell therapy. Patients with radiosensitive SCID due
to mutations in DCLRE1C experience significant long-term
sequelae including growth, endocrine and dental abnormalities,
pancreatic insufficiency, pulmonary fibrosis, as well as increased
mortality, if conditioning regimens contain alkylating agents
(1, 32). On the other hand, unconditioned transplants result
in poor immune reconstitution (vide supra), and the best
approach to treating these patients has yet to be determined.
For Artemis deficient SCID, but also similar vulnerable patients,
innovative targeted therapy directed toward the stem cell niches
on marrow, and thymus using antibody-based conditioning (33–
35) may achieve some myeloid engraftment without the chemo-
conditioning associated toxicities.
Patients with ADA-deficiency, a systemic metabolic disease
in which HSCT only corrects the immune defect, cognitive,
behavioral, or other neurological outcomes appear not to be
affected by transplantation, although it is not possible to know
if there is some amelioration (36–38). Similarly, SCID variants
caused by DNA ligase IV and Cernunnos are associated with
an intrinsic defect associated with long term neurological
impairment which will not be corrected by HSCT. Many patients
with reticular dysgenesis have an associated sensorineural
deafness, related to the defect in adenylate kinase 2, which is
not corrected by HSCT but may be ameliorated by cochlear
implants (39, 40).
Patients with IL-2Rγ- and JAK3-deficient SCID are at
risk of developing extensive cutaneous human papillomavirus-
associated warts which are recalcitrant to treatment, and not
clearly associated with degree of donor chimerism and the level
of T-lymphocyte reconstitution (41, 42) but also seen with low
numbers of NK cells. Although the pathophysiologic mechanism
is not completely understood, evidence has been provided that
lack of the common γ chain function in non-hematologic cells,
i.c., keratinocytes may impair the secretion of chemokines that
may guide the influx of protective immune cells. A canine model
of IL-2Rγ-deficient SCID demonstrates a similar problem, in
which malignant transformation has been demonstrated (43)—
patients will require careful long-term follow up.
Non-SCID Immunodeficiencies
Data on long-term follow up and immune function in non-
SCID primary immunodeficiencies are more scarce than for
SCID. Non-SCID patients usually require full or reduced
intensity chemotherapy conditioning to achieve donor stem cell
engraftment and myeloid chimerism for cure of their immune
disorder. In contrast to SCID where mixed or split chimerism
as a result of the selective growth advantage of donor T- and B
lymphocytes may already be curative this does not necessarily
apply for non-SCID immunodeficiencies. In a number of these
disease categories described hereafter, mixed donor/recipient
stem cell chimerism may result in only partial correction of
the immune disorder and thus occurrence or persistence of
concomitant long term complications.
The possibly unfavorable impact of mixed chimerism on
correction of the immune disorder has been reported in Wiskott
Aldrich syndrome, a syndromal combined immune deficiency
due to defects in the WASP gene which plays a pivotal role
in actin cytoskeleton. There is no selective advantage to cells
harboring the wild type gene, and so partial donor stem cell
chimerism results in a mixed recipient/donor population of
antigen presenting cells, and lymphocytes. The presence of mixed
donor and recipient chimerism has been reported to be associated
with late onset autoimmunity in these patients (44, 45). Although
the exact pathophysiologic mechanism for this autoimmunity
remains to be defined it seems best to aim to achieve high-level
or complete donor chimerism.
In the X-linked form of chronic granulomatous disease
recent data suggest that, because of random lyonisation, female
carriers of X-linked chronic granulomatous disease are at
significant risk of experiencing autoimmunity, fatigue, anxiety
and depression, likely because of inflammation caused by the
genetically faulty phagocytes (46–48). Neutrophil function of
<10% was highly associated with an increased risk of infection
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(47). Although to date, there are no reported similar symptoms in
transplanted patients with mixed donor chimerism, nevertheless,
these findings suggest that high or complete donor chimerism
is desirable, and ideally X-linked disease carriers are not used as
donors if other suitable donors are available.
A growing group of primary immune disorders that may
benefit from allogeneic stem cell therapy and may be even
gene therapy is represented by patients with monogenic diseases
associated with autoimmunity and inflammatory symptoms.
Whilst the numbers of patients reported are few, data are
emerging to suggest that residual dysfunctional host immunity
in these immune dysregulation diseases may cause persistent
autoimmunity and inflammation and therefore high or complete
donor chimerism may be required to abolish disease symptoms,
especially in those diseases where the genetic defect results on
an activated (gain-of-function) instead of a non-functional gene
product. Diseases thus described include Activated PI3K Delta
Syndrome (49), CTLA4 deficiency (50), LRBA deficiency (51),
and STAT1 gain-of-function disease (52). The degree of donor
chimerism required to cure these different disease entities is
yet to be determined. However, based on the pathophysiologic
mechanism of some of these diseases, full donor chimerism
may be required to avoid disease manifestations due to residual
recipient immunity.
Complications in SCID and Non-SCID
Infertility and Other Endocrine Complications
Similar as for many other HSCT indications requiring
chemotherapy-based conditioning, a significant concern
is that of fertility. There are few data regarding this issue
specifically in patients transplanted for PID, partly because a
long follow up is required before the reproductive capability of
patients transplanted as young children is known, should the
patient even wish to have children. Furthermore, conditioning
regimens evolve over time, and the fertility of patients now
under investigation often reflects historic conditioning regimens.
Finally, there may be differences in fertility outcomes depending
on whether chemotherapy was given to a young infant or an
adolescent. In one study of patients, including 68 patients
transplanted for non-malignant disease, spontaneous puberty
was achieved in all males, and 90% of females who received a
reduced intensity conditioning regimen containing fludarabine
and melphalan, compared with 56% of females, and 89% of males
who received a myeloablative regimen containing busulfan,
and cyclophosphamide (53). In a recent study documenting
transplant outcomes of 55 children and adolescents undergoing
stem cell transplantation for chronic granulomatous disease
from a single center, 6 of 11 survivors older than 21 years at
the time of the study had experienced successful unassisted
pregnancy themselves or with their partner, of whom 4 had
received busulfan and cyclophosphamide, 1 received busulfan
and fludarabine, and 1 received fludarabine and melphalan (54).
Two adults transplanted for chronic granulomatous disease
were reported as fathering children after receiving a targeted
dose regimen of busulfan with fludarabine (5). A recent study
of the European Society for Blood and Marrow Transplantation
suggests that gonadal damage may be less following treosulfan-
based conditioning compared to busulfan-based conditioning,
although the number of patients receiving treosulfan was
much smaller (55). Although these data are few, they suggest
that infertility is not inevitable following conditioned HSCT
for PID, and that the outlook may be considerably better
than previously feared. There may be differences between
conditioning regimens, and careful long term follow up should
be continued.
Thyroid dysfunction may occur as an immune-mediated
manifestation of residual primary disease or due to
chemotherapy related toxicity after HSCT and not related
to the underlying immune disorder (56).
Secondary Malignancies
A survey by the European Society for Blood and Marrow
Transplantation has estimated the incidence of myelodysplastic
syndrome or acute myeloid leukemia to be 1.2:1,000 in
transplants for malignancy, mostly occurring within 4
years of HSCT (57). However, these patients present with
malignancy, usually receive more intense chemotherapy
than that administered as preparative pre-conditioning, and
often have irradiation as part of their treatment. The risk
of a non-post-transplant lymphoproliferative malignancy
post-transplantation in patients who were transplanted
for PID is less well-understood. The presence of a PID is
associated with an increased risk of malignancy, around 4–5
times greater than in age-matched controls (58). Risks of
developing a malignancy post-transplantation may be related
to the underlying genetic disease, the tissue distribution of
genetic defect (confined to the hematopoietic compartment
or more wide-spread), previous graft vs. host disease, viral
infections, and the extent of donor chimerism, and quality
of restored immune function. Three studies together found
21 of 3,340 (0.6%) patients developed a malignancy (59–61).
Interestingly, in a large series of patients transplanted for
systemic DNA double strand-breakage repair disorders, which
predispose to malignancy, there were no reported cases of
secondary tumors, although median follow up was only 35
months (62). Collectively, these data demonstrate that there
is a small but real risk of malignancy developing in this
post-transplant cohort and re-enforce the need for careful
long term surveillance. This will be particularly important
for patients in whom malignancy risk is a significant part of
the immunodeficiency, such as those patients with systemic
DNA double strand-breakage repair disorders, or cartilage
hair hypoplasia.
Quality of Life
For many years, studies of patients receiving hematopoietic stem
cell transplantation for PID have concentrated on survival, and
more recently on the quality of immune reconstitution. Long-
term quality of life is an important consideration for patients
transplanted for SCID. There are few studies examining this,
and whilst one found a diminished quality of life compared
to normal controls (38), two others found that quality of life
was related to requirement of on-going treatment, particularly
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immunoglobulin replacement, with those patients who were on
no medication reporting a normal life quality (20, 21). Both
in SCID and non-SCID patients, patient reported outcome on
quality of life is an important measure of treatment outcome,
largely ignored in this field. There are no studies comparing
quality of life before and after transplantation, and only one
that compares transplanted, and non-transplanted age-matched
pediatric cohorts in chronic granulomatous disease (63). This
study showed a normal quality of life in patients who had
been transplanted, compared with those receiving conventional
therapy. In the last decade HSCT has become an increasingly
safe therapeutic modality. In addition to the traditional severe
immune deficiency syndromes in which survival is the primary
goal, HSCT is more often considered in the broadening spectrum
of patients with severe/profound but not-acute life threatening
primary immune disorders. In these chronic disabling diseases
HSCT primarily aims to improve quality of life and add value
both from the patient and physician perspective. More studies
performed in close collaboration between physicians and patients
are required in the growing field of these rare primary immune
disorders to measure the impact of stem cell transplantation and
alterative (e.g., biologicals/GT) on long term disease control as
well as quality of life.
CONCLUSION
There is no doubt that hematopoietic stem cell transplantation
has saved and transformed the lives of many patients with
PID. However, although many patients are able to subsequently
live normal lives, significant post-transplant sequelae reduce
life expectancy, or impair the quality of life in a subgroup
of patients. Given that many patients have extremely rare
immunodeficiencies, the number of patients in follow up is small,
with a short time period of post-transplant follow up. Continued
careful observation and enhanced surveillance is required to
learnmore about the effects of our transplant techniques on these
patients, and to improve long term outcomes.
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